{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:43:11Z","timestamp":1777876991108,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Telemedicine Reports"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>During the COVID-19 pandemic, use of telemedicine (TM) increased dramatically, but it is unclear how use varies by characteristics of people with Alzheimer\u2019s disease (AD), multiple sclerosis (MS), or Parkinson\u2019s disease (PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This cross-sectional study used US PharMetrics Plus commercial claims data from January 1, 2019, to December 31, 2021. TM use (\u22651 Current Procedural Terminology code) was assessed in each study year (2019, 2020, and 2021) among people with \u22651 inpatient or \u22652 outpatient diagnosis codes \u226530 days apart for AD, MS, or PD. Any TM use and disease-related visits (AD, MS, or PD diagnosis code within TM claim) were summarized, and characteristics of TM users versus nonusers during the pandemic (2020 and 2021) were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among people with AD, MS, or PD, 0.9% used TM in 2019 versus 58.0% in 2020 and 42.5% in 2021. Among TM users in 2020 and 2021, the majority had TM visits related to their neurological disorder (73.2% and 64.6%, respectively). During the pandemic, approximately 25% of total TM visits (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 296,434) were provided by a neurologist. Mean (SD) age of TM users was similar to nonusers (60.5 [15.1] and 61.5 [15.3] years), but TM users were more likely to be female (62% vs 60%), enrolled in Medicare (33% vs 30%), and reside in western (64.2% vs 35.8%) or eastern (61.0% vs 39.0%) regions versus nonusers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although results indicate expanded use of and access to TM among people with AD, MS, or PD, differences in patient and health care provider characteristics for TM use were notable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/tmr.2024.0030","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:06:01Z","timestamp":1723550761000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Telemedicine Use Before and During the COVID-19 Pandemic in People with Alzheimer\u2019s Disease, Multiple Sclerosis, or Parkinson\u2019s Disease: A Cross-Sectional Study Using US Commercial Claims Data"],"prefix":"10.1177","volume":"5","author":[{"given":"Anisha M.","family":"Patel","sequence":"first","affiliation":[{"name":"Genentech Inc., South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schuldt","sequence":"additional","affiliation":[{"name":"Genentech Inc., South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise M.","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Genentech Inc., South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan R.","family":"Cobb","sequence":"additional","affiliation":[{"name":"Genentech Inc., South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Win","sequence":"additional","affiliation":[{"name":"Genentech Inc., South San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7463-6787","authenticated-orcid":false,"given":"Marisa P.","family":"McGinley","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4152"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.31"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318294b1cf"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.4468"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008708"},{"key":"e_1_3_6_7_2","volume-title":"The Role of Telehealth in an Evolving Health Care Environment: Workshop Summary","author":"Board on Health Care Services, Institute of Medicine","year":"2012","unstructured":"Board on Health Care Services, Institute of Medicine. The Role of Telehealth in an Evolving Health Care Environment: Workshop Summary. National Academies Press: Washington, DC; 2012."},{"key":"e_1_3_6_8_2","unstructured":"American Medical Association. 2021 Telehealth survey report. 2021. Available from: https:\/\/www.ama-assn.org\/system\/files\/telehealth-survey-report.pdf [Last accessed: March29 2024]."},{"key":"e_1_3_6_9_2","unstructured":"American Academy of Neurology. Telehealth. 2021. Available from: https:\/\/www.aan.com\/practice\/telehealth [Last accessed: March29 2024]."},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.30.2.464"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.3844"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12354"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.2666"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.2234"},{"key":"e_1_3_6_15_2","unstructured":"Rock Health. Digital health consumer adoption report 2020. Available from: https:\/\/rockhealth.com\/insights\/digital-health-consumer-adoption-report-2020\/ [Last accessed: March15 2024]."},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.01786"},{"key":"e_1_3_6_17_2","unstructured":"IQVIA PharMetrics\u00ae Plus. Fact sheet. 2022. Available from: https:\/\/www.iqvia.com\/locations\/united-states\/library\/fact-sheets\/iqvia-pharmetrics-plus [Last accessed: March29 2024]."},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29894"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"issue":"2","key":"e_1_3_6_20_2","article-title":"The COVID-19 Healthcare Coalition Telehealth Impact Study: Keynote","volume":"7","author":"Campion FX","year":"2022","unstructured":"Campion FX. The COVID-19 Healthcare Coalition Telehealth Impact Study: Keynote. THMT, 2022; 7(2); doi: 10.30953\/tmt.v7.334. Available from: https:\/\/telehealthandmedicinetoday.com\/index.php\/journal\/article\/view\/334 [Last accessed: April 4, 2024].","journal-title":"THMT"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5873"},{"key":"e_1_3_6_22_2","unstructured":"National Multiple Sclerosis Society. Who gets MS? Available from: https:\/\/www.nationalmssociety.org\/What-is-MS\/Who-Gets-MS [Last accessed: March15 2024]."},{"key":"e_1_3_6_23_2","unstructured":"Parkinson\u2019s Foundation. Statistics. Available from: https:\/\/www.parkinson.org\/understanding-parkinsons\/statistics [Last accessed: March15 2024]."},{"key":"e_1_3_6_24_2","unstructured":"Medicare. Telehealth. Available from: https:\/\/www.medicare.gov\/coverage\/telehealth [Last accessed: March29 2024]."},{"key":"e_1_3_6_25_2","unstructured":"Telehealth.HHS.gov. Telehealth policy changes after the COVID-19 public health emergency. Available from: https:\/\/telehealth.hhs.gov\/providers\/telehealth-policy\/policy-changes-after-the-covid-19-public-health-emergency [Last accessed: March15 2024]."},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11623-w"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2019.0065"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053440"},{"key":"e_1_3_6_29_2","unstructured":"Archambault J Nastasi V. State policy agenda for telehealth innovation. Available from: https:\/\/reason.org\/policy-brief\/state-policy-agenda-for-telehealth-innovation\/ [Last accessed: March15 2024]."},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.06.577"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.05051"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31640"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1730026"}],"container-title":["Telemedicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/tmr.2024.0030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/tmr.2024.0030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/tmr.2024.0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:38:08Z","timestamp":1777588688000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/tmr.2024.0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["10.1089\/tmr.2024.0030"],"URL":"https:\/\/doi.org\/10.1089\/tmr.2024.0030","relation":{},"ISSN":["2692-4366","2692-4366"],"issn-type":[{"value":"2692-4366","type":"print"},{"value":"2692-4366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"article-number":"tmr.2024.0030"}}